BSX stock forecast, quote, news & analysis
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Why Boston Scientific (BSX) Is Down -12% in the Last 30 Days
Key Takeaways
- BSX stock declined -12% over the past 30 days amid concerns over slowing growth in electrophysiology (EP) and WATCHMAN segments.
- Over the past quarter, the stock fell -27%, reflecting broader challenges including disappointing trial results and cautious guidance.
- Q1 2026 earnings beat estimates with 9.4% organic revenue growth and $0.80 adjusted EPS, but lowered full-year outlook triggered sell-offs.
- Analyst price target cuts post-earnings contributed to downward pressure, despite overall buy consensus.
- Sector headwinds in medical devices and shifting market sentiment amplified the price decline.
Boston Scientific (BSX) Company Overview and Market Position
Boston Scientific Corporation (BSX) is a global medical technology company specializing in less-invasive devices for treating various medical conditions. Its core business model focuses on developing, manufacturing, and marketing innovative products across segments like cardiovascular, endoscopy, urology, neuromodulation, and electrophysiology (EP). Key products include the WATCHMAN left atrial appendage closure (LAAC) device for stroke prevention in atrial fibrillation patients and the FARAPULSE pulsed field ablation (PFA) system for heart rhythm disorders.
In the competitive medical device industry, Boston Scientific holds a strong position with market-leading products and ongoing investments in R&D. Its exposure to high-growth areas like EP and structural heart helps explain recent stock behavior, as any slowdowns in these segments directly impact revenue growth and investor confidence.
Boston Scientific (BSX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BSX stock has dropped approximately -12%, moving from around $61 in early April to a recent close near $54. The decline has been volatile and trend-driven downward, with sharp drops following earnings and analyst reactions.
In the past quarter, the stock fell -27%, from about $74 in early February to current levels. This range-bound to sharply declining movement reflects sustained selling pressure amid operational headwinds.
What Drove BSX Stock Price in the Last 30 Days
The primary catalyst for BSX's 30-day decline was the Q1 2026 earnings release on April 22, which showed solid results—$5.203 billion in net sales (up 11.6% reported, 9.4% organic) and adjusted EPS of $0.80—but included a lowered full-year guidance. Organic growth outlook was cut to 6.5%-8% from prior 10%-11%, and adjusted EPS to $3.34-$3.41, citing unanticipated headwinds in EP, WATCHMAN, and Urology segments.
Post-earnings, numerous analysts lowered price targets (e.g., Canaccord to $71, Needham to $77, Wells Fargo to $75), reflecting concerns over these slowdowns. Market sentiment shifted negatively, with heavy put volume and downgrades like Daiwa to Neutral. Sector influences, including broader medical device pressures, exacerbated the drop.
What Drove BSX Stock Performance Over the Last Quarter
The quarter's -27% decline stemmed from larger narratives like the February 4 Q4 2025 earnings, where despite beats ($5.286 billion revenue, $0.80 adjusted EPS), cautious 2026 guidance disappointed investors, causing a sharp plunge. March 30 brought further pressure from underwhelming clinical trial results and a Raymond James downgrade citing U.S. EP and WATCHMAN slowdowns.
Macroeconomic factors, such as potential rate sensitivity in healthcare spending, and competitive dynamics in medtech contributed. Institutional selling amid YTD underperformance (down over 40%) amplified the trend, with EP and WATCHMAN no longer driving outsized growth.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. This curated section highlights only the most relevant and high-performing bots based on recent metrics like win rate, average return, and consistency. Bots differ in strategies—ranging from trend-following and mean reversion to momentum and volatility-based approaches—and timeframes, including day trading, swing trading, and long-term positions. Performance data is transparently displayed with backtested and live results, helping users identify tools suited to their risk tolerance and goals. Explore the page to discover bots potentially applicable to stocks like BSX and enhance your trading strategy.
BSX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q2 earnings for updates on EP recovery, WATCHMAN adoption, and Urology trends. Upcoming product launches, such as enhancements to FARAPULSE and WATCHMAN FLX Pro, could influence sentiment. Industry developments in structural heart and ablation technologies remain key. Macro factors like interest rates affecting healthcare demand and regulatory approvals warrant attention. Potential risks include persistent segment headwinds or competitive pressures from peers like MDT, while catalysts may arise from margin expansion or M&A (mergers and acquisitions) activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
BSX's RSI Indicator ascending out of oversold territory
The RSI Oscillator for BSX moved out of oversold territory on May 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 344 cases, the price rose further within the following month. The odds of a continued upward trend are .
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on April 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BSX entered a downward trend on May 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.078) is normal, around the industry mean (12.607). P/E Ratio (22.406) is within average values for comparable stocks, (50.865). Projected Growth (PEG Ratio) (0.647) is also within normal values, averaging (1.650). BSX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). P/S Ratio (3.883) is also within normal values, averaging (36.374).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices